Subject: A survey to assess the usage pattern of FDC of Paroxetine and clonazepam in the management of comorbid anxiety and depression in India
Major depressive disorder (MDD) is a debilitating disease that is characterized by at least one discrete depressive episode lasting at least 2 weeks and involving clear-cut changes in mood, interests and pleasure, changes in cognition and vegetative symptoms. Depression is a common mental health disorder that can affect both the mental and physical health. The number of incident cases of depression worldwide increased from 172 million in 1990 to 258 million in 2017, representing an increase of 49.86%. In 2017, 197·3 million people had mental disorders in India, including 45·7 million with depressive disorders and 44·9 million with anxiety disorders.
Anxiety is common among older adults with depressive disorders, both as a symptom and as a comorbid disorder. The prevalence of comorbid anxiety in late-life depression from related studies ranges from 0.9% to 47.5%
Anxiety and depression often co-occur and their comorbidity is commonly seen in MDD patients. Anxiety disorders are the most common comorbid mental health disorders, with comorbidity estimates ranging from 15% to 75%. Hence, combination treatments have become the norm in clinical practice for treating anxiety and depression. Most commonly used clinical strategy for comorbid depression and anxiety is to use combination of SSRIs and benzodiazepines.
Co-administration of benzodiazepines and antidepressants like paroxetine and clonazepam may have a number of potential benefits including:
- Treatment of anxiety symptoms during the temporal lag in therapeutic efficacy with initiation of antidepressant treatment
- Reduction in the anxiety-like symptoms associated with antidepressant initiation
- Possible synergistic or additive therapeutic effects
This survey is conducted to assess the usage pattern of FDC of Paroxetine and clonazepam in the management of comorbid anxiety and depression in India
As you will be spending some extra time to give your feedback on the questionnaire based on your clinical experience, we offer to pay you by cheque a professional fee of Rs {{$contractAmount}}, on receiving the completed Survey Questionnaire Form from you.
We trust you and we are partners in promoting safe and effective drug therapy. In that spirit we hope you will consent to participate in this study. If you do, please sign and return the enclosed reply along with your visiting card for accuracy of records.
|
}}){kind=logo}
}})